Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0FJ9W
|
||||
| Former ID |
DIB016717
|
||||
| Drug Name |
KB-004
|
||||
| Synonyms |
Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Hematological malignancies [ICD9: 200-209; ICD10:C81-C86] | Phase 1/2 | [1] | ||
| Company |
KaloBios Pharmaceuticals Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Epha3 tyrosine kinase receptor | Target Info | [2] | ||
| KEGG Pathway | Axon guidance | ||||
| Pathway Interaction Database | EphrinA-EPHA pathway | ||||
| EPHA forward signaling | |||||
| Reactome | EPH-Ephrin signaling | ||||
| EPHA-mediated growth cone collapse | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| WikiPathways | NRF2 pathway | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01211691) Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF). U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Kalobios. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.